This paper reviews recent patents and development related to bromocriptine and other dopaminergic agents, being used or suggested for use in the management of diabetes. The article discusses the contribution of dopaminergic pathways to glucose, energy and weight homeostasis. The mechanism of action of bromocriptine, its pharmacological properties, efficacy, safety and tolerability are assessed. The article also covers recent patents which may be utilized to improve the efficiency and tolerability of dopamine-based therapy in diabetes mellitus.
Keywords: Type 2 diabetes, obesity, bromocriptine, dopamine, dopaminergic agents, epidemic, insulin, Ominous Octet, gastrointestinal tract, kidney, brain, neurohormones, neurotransmitters, substantia nigra, ventral tegmental area, hypo-thalamus, mesolimbic path-ways, tonic, sexual gratification, Syrian hamsters, swine, drugs, pleiotropic, antipsychotics act, ergot alkaloids, Parkinson's disease, prolactinoma, acromegaly, gynaecological indications, peripartum cardiomyopathy, serum triglycerides, cyclosporine, plasma glucose, hypocaloric diet, placebo, syncopal migraine, lactation, giddiness
Rights & PermissionsPrintExport
Published on: 01 March, 2012
Page: [61 - 65]